Search
Zucapsaicin
go.drugbank.com/drugs/DB09120ApprovedWithdrawnIt is a modulator of transient receptor potential cation channel subfamily V member 1 (TRPV-1), also known as the vanilloid or capsaicin receptor 1, that reduces pain and improves articular functions. … Zucapsaicin was approved by the Health Canada in 2010 as topical cream marketed under the brand name Zuacta but currently not FDA-approved.
Levamisole
go.drugbank.com/drugs/DB00848ApprovedInvestigationalVet approvedWithdrawn[A178117] It was manufactured by _Janssen_ and first used in 1969 as an agent to treat worm infestations[A178123] Levamisole was approved by the FDA in 1990 as an adjuvant treatment for colon cancer. … [L6232] Prior to this, levamisole was used as an antirheumatic therapy in the 1970s and 1980s for patients with rheumatoid arthritis.
Products: Ergamisol Tab 50mgPegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic … The pegylation of pegaspargase allows access to the enzyme's active sites while limiting reticuloendothelial system uptake and reducing immune detection, and it also increases the half-life of L-asparaginase
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalTixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.
Cefiderocol
go.drugbank.com/drugs/DB14879ApprovedInvestigational[A189057] It represents a significant addition to antibacterial treatment option as it has proven to be effective *in vitro* against multidrug resistant strains including extended spectrum β-lactamase … [L10893] It is indicated for use in complicated urinary tract infections in patients with limited or no alternative treatments available.
Carbocromen
go.drugbank.com/drugs/DB13279ApprovedWithdrawnCarbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].
Black cohosh
go.drugbank.com/drugs/DB13975ApprovedInvestigationalBlack cohosh has a long history of use. Native Americans used it for its purported benefits in treating musculoskeletal pain, fever, cough, pneumonia, sluggish labor, and menstrual irregularities. … positive as expected.
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnIn a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates … Doripenem injection was approved by the FDA in 2007 to treat complicated urinary tract and intra-abdominal infections.
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalChikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.[A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus. … In late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection.